文献・資料をご希望の際は、資料請求ページの備考欄に見出し番号（下記リストの赤色の数字）を入力の上、ご連絡ください。

資料請求はこちら ▶

慢性腎臓病（CKD）関連文献 一覧 【新着順】

• 224 Comparison of Urinary Liver Fatty Acid Binding Protein Level and Pathologic Biopsy Findings 1 Year After Kidney Transplantation. Transplant Proc. 2024
  doi: 10.1016/j.transproceed.2023.12.016. PubMed
• 218 Urinary Liver-Type Fatty Acid Binding Protein, a Biomarker for Disease Progression, Dialysis and Overall Mortality in Chronic Kidney Disease. J Pers Med. 2023
  doi: 10.3390/jpm13101481. PubMed
• 214 Cross-Sectional and Longitudinal Associations between Skin Autofluorescence and Tubular Injury Defined by Urinary Excretion of Liver-Type Fatty Acid-Binding Protein in People with Type 2 Diabetes. Biomedicines. 2023
  doi: 10.3390/biomedicines11113020. PubMed
• 211 Elevated urinary angiotensinogen excretion links central and renal hemodynamic alterations. Sci Rep. 2023
  doi: 10.1038/s41598-023-38507-w PubMed
• 210 Association of urinary liver-type fatty acid-binding protein with outcomes after adrenalectomy for unilateral primary aldosteronism. Clin Chim　Acta.2023
  doi: 10.1016/j.cca.2023.117465. PubMed
• 207 Increased urinary albumin leakage is related to injuries of glomerular glycocalyx and podocytes, and associated with tubular dysfunction in preeclampsia. Pregnancy Hypertens.2023
  doi: 10.1016/j.preghy.2023.02.001. PubMed
• 206 Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments. J Am Heart Assoc.2023
  doi: 10.1161/JAHA.122.028146. PubMed
• 205 Association of urinary liver-type fatty acid-binding protein with renal functions and antihyperglycemic drug use in type 2 diabetic nephropathy patients. Int Urol Nephrol.2023
  doi: 10.1007/s11255-023-03532-1. PubMed
• 203 Clinical utility of tubular markers in kidney disease: a narrative review. J Lab Precis Med.2022
  doi: 10.21037/jlpm-22-24 JLPM
• 200 Performance of urinary liver-type fatty acid-binding protein in diabetic nephropathy: A meta-analysis. Front Med (Lausanne).2022
  doi: 10.3389/fmed.2022.914587 PubMed
• 199 Effects of dietary phosphorus concentration and phosphate salt form on renal tubule function in unilateral nephrectomized rats . Nutr Health.2022
  doi: 10.1177/02601060221122223 PubMed
• 196 Early, Noninvasive Clinical Indicators of Kidney Prognosis in Primary Nephrotic Syndrome: A Retrospective Exploratory Study . Int J Nephrol.2022
  doi: 10.1155/2022/2718810 PubMed
• 190 Biomarkers for the early prediction of contrast-induced nephropathy after percutaneous coronary intervention in adults: A systematic review and meta-analysis. Angiology.2022
  doi: 10.1177/00033197211039921. PubMed
• 189 Usefulness of urinary tubule injury markers for predicting progression of renal dysfunction in patients with type 2 diabetes and albuminuria: The Fukuoka Diabetes Registry. Diabetes Res Clin Pract.2022
  doi: 10.1016/j.diabres.2022.109840. PubMed
• 182 Tubular Injury Causing Protracted Glycosuria Following Withdrawal of a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor: A Possible Role in the Development of Protracted Hypoglycemia and Ketoacidosis. Tohoku J Exp Med.2021
  doi: 10.1620/tjem.255.291. PubMed
• 179 Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial. J Diabetes Res.2021
  doi: 10.1155/2021/7382620. PubMed
• 178 Exercise Ameliorates Diabetic Kidney Disease in Type 2 Diabetic Fatty Rats. Antioxidants (Basel).2021
  doi: 10.3390/antiox10111754. PubMed
• 176 Clinical evaluation of urinary liver-type fatty acid-binding protein for the diagnosis of renal diseases in dogs. J Vet Med Sci.2021
  doi: 10.1292/jvms.20-0698. PubMed
• 174 Amniotic Fluid L-Type Fatty Acid-Binding Protein in Predicting Fetal Condition. Tohoku J Exp Med.2021
  doi: 10.1620/tjem.254.267. PubMed
• 168 Renal hemodynamics across the adult lifespan: Relevance of flow pulsatility to chronic kidney disease. Exp Gerontol.2021
  doi: 10.1016/j.exger.2021.111459. PubMed
• 166 Relationship of urinary liver-type fatty acid-binding protein with cardiovascular risk factors in the Japanese population without chronic kidney disease: Sasayama study. BMC Nephrol.2021
  doi: 10.1186/s12882-021-02398-8. PubMed
• 165 Preliminary study of urinary excretion of liver-type fatty acid-binding protein in a cat model of chronic kidney disease. Can J Vet Res.2021
  PubMed
• 164 Evaluation of urinary L-FABP as an early marker for diabetic nephropathy in type 2 diabetic patients. J Med Biochem.2020
  doi: 10.2478/jomb-2019-0037. PubMed
• 163 Liver-type fatty acid-binding protein and neutrophil gelatinase-associated lipocalin in cats with chronic kidney disease and hyperthyroidism. J Vet Intern Med.2021
  doi: 10.1111/jvim.16074. PubMed
• 162 Predictive value of novel biomarkers for chronic kidney disease among workers occupationally exposed to silica. Toxicol Ind Health.2021
  doi: 10.1177/0748233721990304. PubMed
• 161 Urinary liver-type fatty acid-binding protein is a predictor of mortality in individuals with type 2 diabetes. Diabet Med.2021
  doi: 10.1111/dme.14527. PubMed
• 160 Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats. Clin Exp Nephrol.2021
  doi: 10.1007/s10157-020-02007-2. PubMed
• 158 Urinary Liver-type Fatty Acid-Binding Protein Predicts Residual Renal Function Decline in Peritoneal Dialysis Patients. Med Sci Monit.2020
  doi: 10.12659/MSM.928236 PubMed
• 157 Novel Urinary Biomarkers and Chronic Kidney Disease After Coronary Angiography: A Prospective Case-Controlled Study. Open Access Maced J Med Sci.2020
  doi: 10.3889/oamjms.2020.4857 OAMJMS
• 154 Longitudinal kidney injury biomarker trajectories in children with obstructive uropathy. Pediatr Nephrol.2020
  doi: 10.1007/s00467-020-04602-7 PubMed
• 152 Increased Urinary Liver-Type Fatty Acid-Binding Protein Level Predicts Major Adverse Cardiovascular Events in Patients with Hypertension. Am J Hypertens.2020 PubMed
• 151 Renal expression and urinary excretion of liver-type fatty acid-binding protein in cats with renal disease. J Vet Intern Med. 2020 PubMed
• 149 Relationship between Urinary Liver-Type Fatty Acid-Binding Protein (L-FABP) and Sarcopenia in Spontaneously Diabetic Torii Fatty Rats. J Diabetes Res.2020 Hindawi
• 148 Effects of exercise on residual renal function in patients undergoing peritoneal dialysis: a post-hoc analysis of a randomized controlled trial. Ther Apher Dial.2020 PubMed
• 146 Evaluation of liver-type fatty acid binding protein (L-FABP) and interleukin 6 in children with renal cysts. Adv Clin Exp Med.2019 PubMed
• 145 The influence of renal function by ibuprofen treatment for patent ductus arteriosus in extremely low-birth-weight infants. Pediatr Int.2019 PubMed
• 144 The Possibility of Urinary Liver-Type Fatty Acid-Binding Protein as a Biomarker of Renal Hypoxia in Spontaneously Diabetic Torii Fatty Rats. Kidney Blood Press Res.2019 PubMed
• 140 Utility of urinary liver-type fatty acid-binding protein as a predictor of renal dysfunction in Japanese patients with HIV receiving tenofovir disoproxil fumarate with low urinary β2 microglobulin levels: a retrospective observational study. J Pharm Health Care Sci.2019 PubMed
• 139 Renoprotective effects of voluntary running exercise training on aldosterone-induced renal injury in human L-FABP chromosomal transgenic mice. Hypertens Res.2019 PubMed
• 138 Effect of linagliptin on oxidative stress markers in patients with type 2 diabetes: a pilot study. Diabetol Int. 2018 PubMed
• 137 Urinary Level of Liver-Type Fatty Acid Binding Protein Reflects the Degree of Tubulointerstitial Damage in Polycystic Kidney Disease. Kidney Blood Press Res. 2018 PubMed
• 134 Urinary liver-type fatty acid-binding protein levels as a potential risk factor for renal dysfunction in male HIV-infected Japanese patients receiving antiretroviral therapy: a pilot study. Int J STD AIDS. 2018 PubMed
• 130 Urinary L-FABP level in children with nephrotic syndrome and tubular dysfunction. Pediatr Int.2018 PubMed
• 129 Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucoselowering-independent manner. BMJ Open Diabetes Res Care.2017 PubMed
• 127 Prediction of contrast induced acute kidney injury using novel biomarkers following contrast coronary angiography. QJM.2018 PubMed
• 126 Role of bardoxolone methyl, a nuclear factor erythroid 2-related factor 2 activator, in aldosterone- and salt-induced renal injury. Hypertens Res.2017 PubMed
• 125 Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensin II type 1a receptor expression. Eur J Pharmacol.2017 PubMed
• 124 Urinary liver-type fatty acid-binding protein is associated with subendocardial viability ratio in middle- and older-aged adults. Clin Exp Hypertens.2017 PubMed
• 121 Urine liver fatty acid binding protein and chronic kidney disease progression. Scand J Clin Lab Invest.2017 PubMed
• 120 Urinary liver-type fatty acid binding protein is an independent predictor of stroke and mortality in individuals with type 1 diabetes. Diabetologia.2017 PubMed
• 119 Current Metabolic Status Affects Urinary Liver-Type Fatty-Acid Binding Protein in Normoalbuminuric Patients With Type 2 Diabetes. JClin Med Res.2017 PubMed
• 116 Utility of urinary tubular markers for monitoring chronic tubulointerstitial injury after ischemia-reperfusion. Nephrology.2017 PubMed
• 113 The association between urinary liver-type fatty acid-binding protein and chronic kidney disease classification in HIV-infected Japanese patients. Clin Exp Nephrol.2016 PubMed
• 111 Role of angiotensin II type 1a receptor in renal injury induced by deoxycorticosterone acetate-salt hypertension. FASEB J.2016 PubMed
• 107 Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study. Cardiovasc Diabetol.15(1): 76, 2016. PubMed
• 106 Renoprotective effect of the xanthine oxidoreductase inhibitor, Topiroxostat,on Adenine-Induced Renal Injury. Am J Physiol Renal Physiol.310(11):F1366-1376, 2016. PubMed
• 104 Clinical utility of urinary liver-type fatty acid binding protein measured by latex-enhanced turbidimetric immunoassay in chronic kidney disease. Clin Chem Lab Med.2016. PubMed
• 102 Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD. Clin Exp Nephrol.20(2): 195-203, 2016. PubMed
• 99 Urinary markers in the early stage of nephropathy in patients with childhood-onset type 1 diabetes. Pediatr Nephrol.31(4):623-631, 2016. PubMed
• 96 Epoetin beta pegol alleviates oxidative stress and exacerbation of renal damage from iron deposition, thereby delaying CKD progression in progressive glomerulonephritis rats. Physiol Rep.3(12), 2015. PubMed
• 95 Urinary liver-type fatty acid-binding protein change in gestational diabetes mellitus. Diabetes Res Clin Pract.109(3): e36-e38, 2015. PubMed
• 94 Urinary Biomarkers and Risk of ESRD in the Atherosclerosis Risk in Communities Study. Clin J Am Soc Nephrol.10(11):1956-1963, 2015. PubMed
• 91 Urinary ACE2 is associated with urinary L-FABP and albuminuria in patients with chronic kidney disease. Scand J Clin Lab Invest.75(5): 421-427, 2015. PubMed
• 89 Does elevation of serum creatinine in patients with chronic hepatitis C under therapy of telaprevir mean renal impairment? Nephrology.10(4):e0122212, 2015. PubMed
• 88 Distinct roles of urinary liver-type Fatty Acid-binding protein in non-diabetic patients with anemia. PLoS One.10(5): e0126990, 2015. PubMed
• 87 Circulating TNF Receptors 1 and 2 Are Associated with the Severity of Renal Interstitial Fibrosis in IgA Nephropathy. PLoS One.10(4): e0122212, 2015. PubMed
• 85 Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. Clin Exp Nephrol.19(6): 1044-1053, 2015. PubMed
• 84 Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus. Diabetologia.58(1): 188-198, 2015. PubMed
• 81 LDL-apheresis contributes to survival extension and renal function maintenance of severe diabetic nephropathy patients: a retrospective analysis. Diabetes Res Clin Pract.106(2): 241-246, 2014. PubMed
• 80 NGAL, L-FABP, and KIM-1 in comparison to established markers of renal dysfunction. Clin Chem Lab Med.52(4): 537-546, 2014. PubMed
• 74 Urinary biomarkers of kidney injury are associated with all-cause mortality in the Women’s Interagency HIV Study (WIHS). HIV Med.15(5): 291-300, 2014. PubMed
• 72 Level of urinary liver-type fatty acid-binding protein is associated with cardiac markers and electrocardiographic abnormalities in type-2 diabetes with chronic kidney disease stage G1 and G2. Heart Vessels.30(3): 362-368, 2014. PubMed
• 71 Nonalbuminuric proteinuria as a biomarker for tubular damage in early development of nephropathy with type 2 diabetic patients. Diabetes Metab Res Rev.30(8): 736-741, 2014. PubMed
• 70 Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir. AIDS Res Hum Retroviruses.30(4): 363-369, 2014. PubMed
• 63 Moderate-intensity single exercise session does not induce renal damage. J Clin Lab Anal.27(3): 177-180, 2013. PubMed
• 62 A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reduces renal tubulointerstitial fibrosis by suppressing PAI-1. Am J Physiol Renal Physiol.305(12): F1796-1803, 2013. PubMed
• 60 Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy. Diabetes Care.36(5): 1248-1253, 2013. PubMed
• 58 Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet Med.29(8): e184-190, 2012. PubMed
• 56 Renoprotective and antioxidant effects of cilnidipine in hypertensive patients. Hypertens Res.35(11): 1058-1062, 2012. PubMed
• 51 Potential Benefit of Statin Therapy for Dyslipidemia with Chronic Kidney Disease: Fluvastatin Renal Evaluation Trial (FRET). Internal Medicine.50(12): 1273-1278, 2011. PubMed
• 50 Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria. Hypertens Res .34: 935-941, 2011. PubMed
• 48 Protective effects of tubular liver-type fatty acid-binding protein against glomerular damage in murine IgA nephropathy. Nephrol Dial Transplant.26(7): 2127-2137, 2011. PubMed
• 45 Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis. Nephrol Dial Transplant.26(11): 3465-3473, 2011. PubMed
• 44 Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients. Diabetes Care.34(3): 691-696, 2011. PubMed
• 41 Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes. Eur J Clin Invest.40(2): 95-102, 2010. PubMed
• 40 Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care.33(6): 1320-1324, 2010. PubMed
• 39 Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urinary L-FABP, and inflammatory and atherosclerosis markers in early-stage chronic kidney disease. Am J Med Sci.339(2): 157-163, 2010. PubMed
• 38 Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy. Kidney Blood Press Res.33(3): 213-220, 2010. PubMed
• 37 Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease. Eur J Clin Invest.40(9): 790-796, 2010. PubMed
• 34 Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy. Nephron Clin Pract.112(3): c148-156, 2009. PubMed
• 33 Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care.32(9): 1684-1688, 2009. PubMed
• 30 Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy. Metabolism.58(8): 1185-1190, 2009. PubMed
• 29 Amelioration of diabetic tubulointerstitial damage in liver-type fatty acid-binding protein transgenic mice. Nephrol Dial Transplant.24(3): 788-800, 2009. PubMed
• 25 Renoprotective effect of telmisartan in patients with chronic kidney disease. Clin Exp Hypertens.30(7): 662-672, 2008. PubMed
• 24 Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy. Clin Nephrol.70(5): 385-392, 2008. PubMed
• 21 Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure. Diabetologia.50(2): 490-492, 2007. PubMed
• 20 Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci.333(6): 321-326, 2007. PubMed
• 19 Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy. Am J Hypertens.20(11): 1195-1201, 2007. PubMed
• 16 Cigarette smoking affects urinary liver-type fatty acid-binding protein concentration in patients with early diabetic nephropathy. Diabetes Care.29(7): 1717, 2006. PubMed
• 15 Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis. Clin Nephrol.65(1): 1-6, 2006. PubMed
• 14 Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria. Diabetes Metab Res Rev.22(5): 385-389, 2006. PubMed
• 13 Effect of Erythropoietin on Urinary Liver-Type Fatty-Acid-Binding Protein in Patients with Chronic Renal Failure and Anemia. Am J Nephrol.26(3): 276-280, 2006. PubMed
• 12 Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease. Am J Nephrol.26(1): 82-86, 2006. PubMed
• 11 Liver-type fatty acid-binding protein attenuates renal injury induced by unilateral ureteral obstruction. Am J Pathol.169(4): 1107-1117, 2006. PubMed
• 10 Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem.284(1-2): 175-182, 2006. PubMed
• 8 Clinical Significance of Urinary Liver-Type Fatty acid-binding Protein in Patients With Diabetic Nephropathy. Diabetes Care.28(18): 2038-2039, 2005. PubMed
• 7 Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease. TAm J Med Sci.330(4): 161-165, 2005. PubMed
• 6 Effect of Pitavastatin on Urinary Liver-Type Fatty acid-binding Protein Levels in Patients With Early Diabetic Nephropathy. Diabetes Care.28(11): 2728-2732, 2005. PubMed
• 5 Urinary liver-type fatty acid-binding protein: discrimination between IgA nephropathy and thin basement membrane nephropathy. Am J Nephrol.25(5): 447-450, 2005. PubMed
• 4 Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: A multicenter trial. J Lab Clin Med.145(3): 125-133, 2005. PubMed
• 3 Urinary excretion of liver fatty acid-binding protein in health-check participants. Clin Exp Nephrol.9(1): 34-39, 2005. PubMed
• 2 Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol.165(4): 1243-1255, 2004. PubMed
• 1 Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med.143(1): 23-30, 2004. PubMed

文献・資料をご希望の際は、資料請求ページの備考欄に見出し番号（下記リストの最初の数字）を入力の上、ご連絡ください。

資料請求はこちら ▶

文献カテゴリー

慢性腎臓病（CKD）　急性腎障害（AKI）　薬剤性腎障害（Toxicology）
薬理学（Pharmacology）　運動（Exercise）　新型コロナウイルス感染症（COVID-19）　日本語総説　ガイドラインなど